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Abstract
Background: Tobacco and alcohol consumption are risk factors for developing head
and neck cancer, and continuation postdiagnosis can adversely affect prognosis. We
explored changes to these behaviors after a head and neck cancer diagnosis.
Methods: Demographic and clinical data were collected from 973 people newly
diagnosed with oral cavity, oropharyngeal, or laryngeal cancer. Tobacco and alcohol
consumption were additionally collected 4 and 12 months later.
Results: The prevalence of high alcohol consumption reduced from 54.3% at diagno-
sis to 41.4% at 12 months, and smoking reduced from 21.0% to 11.7%. Changes in
behavior were dynamic, for example, 44% of smokers at 12 months were not smok-
ing at diagnosis or 4 months. Several factors were associated with alcohol
consumption, whereas only tumor site and comorbidities were associated with
smoking.
Conclusion: A diagnosis of head and neck cancer can result in important changes in
alcohol consumption and smoking prevalence. However, these changes are dynamic
in the first year after diagnosis.
KEYWORD S
alcohol, head and neck cancer, health behaviors, smoking, teachable moment
1 | INTRODUCTION
Head and neck cancer is an important cause of mortality and
morbidity worldwide.1,2 In the United Kingdom, survival
rates for some head and neck cancers have improved in the
last 25 years.3,4 The reasons for these improvements are
unclear but could include alterations in lifestyle behavior
after treatment.
Tobacco and alcohol consumption are established risk
factors for developing head and neck cancer.5–8 Continued
tobacco and alcohol consumption after treatment for head
and neck cancer is a risk factor for the development of sec-
ond primary cancers,9,10 and decreased 5-year survival
rates.11 Tobacco consumption during treatment is also asso-
ciated with poorer outcomes of surgical12,13 and nonsurgical
treatments.11,14–16 Tobacco and alcohol consumption are,
therefore, potentially important modifiable factors that may
influence disease recurrence and survival.
A diagnosis of head and neck cancer may be a “teachable
moment,” which leads individuals to spontaneously adopt
risk-reducing health behaviors.17 One study suggested that
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approximately 50% of people who were smokers or problem
drinkers when diagnosed with head and neck cancer had quit
smoking or reduced their alcohol consumption to within safe
limits 12 months after diagnosis with no specific health
behavior advice above usual care.18 Smoking and heavy
alcohol consumption are interrelated,19 heavy alcohol
drinkers are less likely to try to stop smoking, and are less
successful if they try.20–22
Previous studies, which included prediagnosis and post-
diagnosis measures of smoking and/or alcohol consumption
after a diagnosis of head and neck cancer, had relatively
small sample sizes (n< 300).18,23–26 Repeated measures of
smoking status postdiagnosis were included in some stud-
ies,18,25,26 but none had repeated measures of postdiagnosis
alcohol consumption. Using data from a large, prospective
clinical cohort, we explored whether people changed their
alcohol and tobacco consumption between diagnosis for
head and neck cancer and 12 months later, and whether these
changes were stable during this period. We also explored
which factors were associated with these changes.
2 | MATERIALS AND METHODS
Data were collected from participants in the Head and Neck
5000 prospective clinical cohort study. Details on Head and
Neck 5000 have been published previously,27,28 and a fully
searchable data dictionary is available online (http://www.
headandneck5000.org.uk/). In brief, the Head and Neck 5000
aimed to recruit 5000 adults newly diagnosed with head and
neck cancer between April 2011 and December 2014 from
76 UK centers. People with lymphoma, skin tumors, or a
recurrence of a previous head and neck cancer were
excluded.27 The study was approved by the National
Research Ethics Committee (South West Frenchay Ethics
Committee, reference 10/H0107/57, November 5, 2010) and
approved by the research and development departments for
participating National Health Service trusts. We collected
data at diagnosis (baseline), and 4 and 12 months after using
self-report questionnaires and data capture forms to record
details from clinical records. Five thousand five hundred
eleven people consented into the study, of whom 138 were
subsequently found to be ineligible. The resultant study sam-
ple contained 5369 people.
2.1 | Inclusion criteria
For this study, we included participants who returned a base-
line “About You” questionnaire, and who had oral cavity,
oropharyngeal, or laryngeal cancer. We excluded people on a
palliative or supportive treatment pathway at diagnosis. This
was a relatively small group and we expected them to have
different motivations to change their health behaviors after
diagnosis than people on a curative treatment pathway. We
also excluded people who would not have been able to com-
plete data at all 3 time points, due to having died before the
12-month data collection or who declined to complete any or
all of the baseline, 4-month, or 12-month questionnaires.
2.2 | Measures
2.2.1 | Health behaviors: Alcohol and
tobacco consumption
Consumption of alcohol and tobacco were recorded through
self-report questionnaires distributed at diagnosis (baseline),
and 4 and 12 months after diagnosis. People who responded
“none” when asked “In a typical week, how many days do
you drink alcohol?” were assumed to consume no units of
alcohol per week. The amount and frequency of consumption
per week of beer, spirits, or wine were combined and con-
verted into standard UK alcohol units per week using the
method described by Zuccolo et al.29 We categorized partici-
pants’ alcohol consumption using the revised UK Depart-
ment of Health guidelines30 and included additional higher
thresholds defined by the “Institute of Alcohol Studies”31 as
well as a category for people who did not consume alcohol.
This resulted in 4 categories of alcohol consumption: low
consumer: (1) nondrinker: 0 units/week; (2) moderate
use:> 0 and 14 units/week; high consumer: (3) harmful
use: women> 14 and 35 units/week, men> 14 and 50
units/week; and (4) hazardous use: women> 35 units/week,
men> 50 units/week.
Tobacco consumption at diagnosis was recorded as “cur-
rent user of tobacco,” “former user of tobacco,” or “never
used tobacco.” In the 4-month and 12-month questionnaires,
tobacco consumption was recorded as “current user” or
“recently quit using tobacco or never used tobacco,” which
were recategorized as “current smoker” and “current non-
smoker,” respectively.
2.3 | Demographic factors
We included the following demographic factors reported in
previous studies to be associated with change in smoking or
alcohol behavior: age, sex, marital status, and education. The
participants’ sex and marital status were recorded in the base-
line “Health and Lifestyle” questionnaire. Marital status was
dichotomized into “married/living with partner” and “single,
divorced, widowed, or separated.” Participants’ age was
derived from their date of birth and date of consent.
2.4 | Clinical data
Tumor site,32 disease stage,32 and the type of treatment
received23,25 have previously been found to be associated
with change in smoking or alcohol behavior and have, there-
fore, been included as potential factors thought to be
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associated with behavior change in our study. We also
included prediagnosis comorbidity. Tumor site was defined
using the categorized International Classification of Disease-
10 codes for tumor location, which have been described previ-
ously.28 Pretreatment clinical TNM classification was catego-
rized into “early stage” (stages I and II) and “advanced stage”
(stages III and IV). Pretreatment comorbidity, using the over-
all comorbidity score from the Adult Comorbidity Evaluation-
27,33 was categorized into “no comorbidity, mild decompen-
sation, or unknown” and “moderate or severe decompensa-
tion.” The actual treatment the participants received was
recorded in the 4-month data capture form. We grouped these
treatments into 4 categories: (1) surgery only; (2) surger-
y1 adjunct therapy; (3) combined chemoradiotherapy; and
(4) radiotherapy only.
2.5 | Study samples
Some participants had missing data, either from nonresponse
to individual questions or from attrition of the cohort over
time due to death or loss to follow-up. The proportion of
“Health and Lifestyle” questionnaires returned at diagnosis
was 74.9%, 73.0% at 4 months, and 58.6% at 12 months
(excluding people who died by 4 and 12 months, respec-
tively). Five people were marked as “lost to follow-up” at 12
months for questionnaire data. We defined our main study
sample as those participants with complete data for expo-
sures and outcomes at all time points.
2.6 | Statistical analysis
In order to determine whether people in the main study sam-
ple differed from people who met the inclusion criteria but
had some missing data, we compared the demographic and
clinical characteristics of these groups. Continuous measures
were compared using t tests and categorical measures com-
pared using chi-square tests. Health behaviors at each time
point were described using proportions. We described the
change in health behaviors from diagnosis to 4 months and
diagnosis to 12 months. We also described behavior trajecto-
ries using all 3 time points to identify whether behaviors
changed during the 12 months and if change occurred early
(by 4 months), late (4-12 months), or was only temporary.
In order to explore associations between proposed risk
factors and change in health behaviors, we stratified analyses
by prediagnosis health behavior. For smoking, we further
divided baseline nonsmokers into “never” and “former”
smokers. For each stratum of prediagnosis health behaviors,
we used binary logistic regression models to calculate unad-
justed odds ratios (ORs) of being in the “unhealthy” behavior
category (being a high consumer of alcohol or current
smoker) as opposed to being in the “healthy” category (low
consumer of alcohol or not current nonsmoker) at 4 months
and at 12 months for each of the proposed risk factors. We
then included risk factors in mutually adjusted binary logistic
regression models. All analyses were undertaken in Stata 14
(StataCorp, 2015).
2.7 | Sensitivity analyses
We repeated our cross-sectional analyses of health behaviors
at each of the time points separately using those respondents
with complete data for exposures and outcomes at that time
point. In order to determine whether recent changes in rec-
ommended alcohol consumption for men affected our find-
ings, we repeated our analyses of alcohol consumption at 4
months and 12 months using the previous guideline for max-
imum alcohol consumption for men of 21 units/week.
3 | RESULTS
3.1 | Description of study samples
From the total Head and Neck 5000 cohort who were con-
firmed as eligible to participate (N5 5373), 4326 people
(80.5%) were diagnosed with oral cavity, oropharyngeal, or
laryngeal cancer and 2916 (67.4%) of these met the inclusion
and exclusion criteria (see Figure 1). Nine hundred seventy-
three (33.4%) of these people had complete data for potential
exposures and health behaviors at diagnosis, 4 months, and
12 months. People with complete data were slightly older,
and more likely to be men, have higher levels of education,
and have early-stage disease than those who met the inclu-
sion criteria but were missing data (Supporting Information
Table S1). The weekly alcohol consumption of people with
complete data was higher at all time points, whereas tobacco
consumption only differed at diagnosis, when people in the
main study sample were more likely to be current smokers
and less likely to be never smokers.
3.2 | Health behaviors at diagnosis,
4 months, and 12 months
3.2.1 | Alcohol
At diagnosis, 54.3% of people (N5 528) in the main sample
consumed more than the recommended weekly maximum
number of units of alcohol and were considered high con-
sumers (Table 1), reducing to 35.2% (N5 342) at 4 months
and increasing slightly to 41.4% (N5 403) at 12 months.
The majority of high alcohol consumers at 4 months were
high consumers at diagnosis (89.2%; 305 of 342), but a third
of low consumers at 4 months were high consumers at diag-
nosis (35.3%; 223 of 631; see Figure 2). Few high consumers
at 12 months were low consumers at diagnosis (9.2%; 37 of
403), but nearly one-third (30.8%; 124 of 403) of high con-
sumers at 12 months had changed from being low consumers
at 4 months.
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3.2.2 | Smoking
At diagnosis, 21.0% of participants (N5 204 of 973) in the
main sample were current smokers, 58.0% (N5 564) were
former smokers, and 21.1% (N5 205) had never smoked
(Table 1). Four months after diagnosis, smoking prevalence
had halved to 10.8% (N5 105), and remained at this level at
12 months (11.7%; N5 114). The 205 people who had never
smoked at diagnosis remained nonsmokers at 4 months
(98.5%) and 12 months (99.5%), and so have been excluded
from descriptions of change in behavior and further analyses.
A quarter of the smokers at 4 months were former smokers
at diagnosis (23.5%; 24 of 102; see Figure 3). Half of the
current smokers at 12 months were smokers at both
FIGURE 1 Flow diagram of the inclusion and exclusion of eligible participants from the Head and Neck 5000 (H&N5000) clinical cohort. 4M, 4
month; 12M, 12month; AY, About You questionnaire, BL, baseline [Color figure can be viewed at wileyonlinelibrary.com]
TABLE 1 Categories of alcohol and tobacco consumption at diagnosis, 4 months, and 12-months
Diagnosis no. of people (%) 4 mo no. of people (%) 12 mo no. of people (%)
Grouped weekly alcohol consumption
“Healthy” drinker (14 units/wk) 445 (45.7) 631 (64.9) 570 (58.6)
Nondrinker 242 (24.9) 415 (42.7) 320 (32.9)
Moderate use 203 (20.9) 216 (22.2) 250 (25.7)
“Unhealthy” drinker (>14 units/wk) 528 (54.3) 342 (35.2) 403 (41.4)
Hazardous use 367 (37.7) 272 (28.0) 327 (33.6)
Harmful use 161 (16.6) 70 (7.2) 76 (7.8)
Tobacco consumption
Current smoker 204 (21.0) 105 (10.8) 114 (11.7)
Formera 564 (58.0) 868 (89.2) 859 (88.3)
Nevera 205 (21.1)
a“Former” and “Never” smokers are combined at the 4-month and 12-month questionnaires.
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diagnosis and 4 months (56%; 63 of 113). A third of the cur-
rent smokers at 12 months were former smokers at 4 months
(31.0%; 35 of 113), of whom nearly half (46%; 16 of 35)
were former smokers at diagnosis. A comparable number but
much smaller proportion (3.7%; 24 of 655) of former smok-
ers at 12 months were current smokers at 4 months.
3.3 | Factors associated with postdiagnosis
behavior change
3.3.1 | Logistic regression models for health
behaviors at 12 months
Health behavior at 12 months was the main outcome of our
logistic regression models (Tables 2 and 3), with results for 4
months included briefly in the text here and in detail in the
Supporting Information Tables S2 and S3). In summary, the
adjusted models found that being men, having a laryngeal
tumor, and being a former or current smoker at diagnosis
were associated with high alcohol consumption at 12
months. People with oropharyngeal tumors were less likely
to restart smoking, whereas continuing to smoke was associ-
ated with being men, having an oral cavity or oropharyngeal
tumor, and having more severe comorbidities at diagnosis.
In adjusted models, irrespective of their alcohol con-
sumption at diagnosis, women were less likely than men to
be high consumers at 12 months (OR 0.48; 95% confidence
interval [CI] 0.19-1.20; P5 .12 and OR 0.36; 95% CI 0.21-
0.59; P< .001 for low and high consumers at diagnosis,
FIGURE 2 Trajectories of alcohol consumption at diagnosis, 4 months, and 12months
FIGURE 3 Trajectories of smoking behavior at diagnosis, 4 months, and 12months
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respectively; Table 2). Increased alcohol consumption at 12
months was much less likely in people with oropharyngeal
cancer compared to oral cavity cancer (OR 0.14; 95% CI
0.04-0.50; P5 .003), and more likely in former smokers
compared with never smokers (OR 2.74; 95% CI 0.95-7.89;
P5 .06). Continued high consumption was more likely in
people with laryngeal cancer compared to oral cavity cancer
(OR 1.95; 95% CI 0.98-3.85; P5 .06) and current compared
with never smokers (OR 2.45; 95% CI 1.23-4.88; P5 .01).
Smoking status at 12 months was only associated with
sex and clinical factors. Among former smokers at diagnosis,
people with oropharyngeal cancer compared to oral cavity
cancer had reduced odds of restarting smoking at 12 months
(OR 0.24; 95% CI 0.07-0.83; P5 .02; Table 3). Continued
smoking at 12 months was less likely in women (OR 0.44;
95% CI 0.19-0.99; P5 .05) and people with laryngeal cancer
compared to oral cavity cancer (OR 0.15; 95% CI 0.05-0.48;
P5 .001). Whereas people with moderate or severe comor-
bidities (OR 3.12; 95% CI 1.39-7.01; P5 .006) were more
likely to continue smoking.
3.4 | Logistic regression models for health
behaviors at 4 months
These results are described in full in the Supporting Informa-
tion. In summary, unlike at 12 months, high alcohol
TABLE 2 Unadjusted and mutually adjusted logistic regression models for odds of consuming alcohol above the recommended limits at 12
months postdiagnosis, stratified by prediagnosis alcohol consumption
Low consumers High consumers
Unadjusted Mutually adjusteda Unadjusted Mutually adjusteda
OR 95% CI P value OR 95% CI P value OR 95% CI P value OR 95% CI P value
Age, ref< 55 y
55-69 0.82 0.36-1.85 .63 0.66 0.28-1.61 .36 1.20 0.76-1.89 .44 1.10 0.67-1.82 .71
701 0.86 0.34-2.15 .74 0.56 0.20-1.61 .28 1.51 0.80-2.84 .20 1.24 0.61-2.50 .56
Sex, ref male
Female 0.46 0.20-1.08 .07 0.48 0.19-1.20 .12 0.41 0.26-0.66 < .001 0.36 0.21-0.59 < .001
Marital status, ref married/cohabiting
Single, divorced, widowed,
or separated
0.82 0.39-1.74 .61 0.83 0.37-1.87 .65 1.14 0.77-1.71 .51 0.96 0.61-1.50 .85
Education, ref school level
Further education 1.47 0.69-3.11 .31 1.76 0.78-3.95 .17 1.27 0.84-1.93 .26 1.39 0.88-2.18 .15
University/poly 1.10 0.43-2.81 .84 1.49 0.51-4.33 .46 1.08 0.66-1.78 .75 1.38 0.80-2.39 .25
Tumor site, ref oral cavity
Oropharynx 0.32 0.12-0.83 .02 0.14 0.04-0.50 .003 0.57 0.37-0.87 .009 0.90 0.52-1.56 .70
Larynx 1.75 0.81-3.79 .16 1.43 0.47-4.32 .53 1.88 1.09-3.26 .02 1.95 0.98-3.85 .06
TNM classification, ref early
Advanced 0.76 0.39-1.50 .43 1.31 0.50-3.40 .58 0.40 0.27-0.59 < .001 0.49 0.28-0.86 .01
Comorbidity, ref none or mild
Moderate or severe 0.87 0.37-2.06 .76 0.74 0.29-1.87 .52 0.96 0.58-1.58 .88 0.85 0.49-1.47 .57
Treatment received, ref surgery only
Surgery1 adjunct 0.59 0.21-1.65 .31 0.91 0.29-2.88 .87 0.46 0.26-0.79 .005 0.65 0.34-1.25 .19
Combined chemoradiotherapy 0.74 0.30-1.82 .51 2.11 0.53-8.36 .29 0.42 0.25-0.70 .001 0.67 0.32-1.39 .28
Radiotherapy only 1.08 0.44-2.66 .87 0.92 0.28-3.03 .89 0.96 0.51-1.78 .89 0.58 0.28-1.24 .16
BL smoking status,
ref never smoked
Current 2.05 0.57-7.35 .27 1.78 0.45-6.96 .41 2.28 1.26-4.16 .007 2.45 1.23-4.88 .01
Former 2.95 1.11-7.86 .03 2.74 0.95-7.89 .06 1.58 0.94-2.63 .08 1.51 0.86-2.66 .16
Abbreviations: BL, baseline; CI, confidence interval; OR, odds ratio; ref, reference.
aMutually adjusted for all exposures and confounders.
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consumption was associated with treatment received, specifi-
cally having surgery. Continued smoking at 4 months was
negatively associated with having advanced-stage cancer and
positively associated with having more severe comorbidities
among both former and current smokers. Resumption of
smoking was associated with not being in a relationship and
with high alcohol consumption at diagnosis.
3.5 | Sensitivity analyses
Health behaviors at each time point were comparable using
time-point-specific study samples (Supporting Information
Table S4) as when using the main “complete case” study
sample (Table 1). Using the previous sex-specific guidelines
for weekly alcohol consumption, the strength of sex associa-
tions with alcohol consumption at 4 months and 12 months
was comparable for initially low consumers at diagnosis (OR
0.42; 95% CI 0.16-1.10; P5 .08 and OR 0.42; 95% CI 0.16-
1.07; P5 .07) and for initially high consumers at 4 months
(OR 0.46; 95% CI 0.27-0.80; P5 .006) but did not persist
for initially high consumers at 12 months (OR 0.79; 95% CI
0.48-1.31; P5 .37).
4 | DISCUSSION
We analyzed data from 973 people with oral cavity, oropha-
ryngeal, or laryngeal cancer, of whom 54% consumed above
TABLE 3 Unadjusted and mutually adjusted logistic regression models for odds of being a smoker at 12 months postdiagnosis, stratified by
prediagnosis smoking status
Former smoker Current smoker
Unadjusted Mutually adjusteda Unadjusted Mutually adjusteda
OR 95% CI P value OR 95% CI P value OR 95% CI P value OR 95% CI P value
Age, ref< 55 y
55-69 0.58 0.25-1.34 .20 0.52 0.22-1.28 .16 1.57 0.81-3.06 .18 1.68 0.78-3.60 .18
701 0.47 0.15-1.46 .19 0.40 0.12-1.40 .15 1.13 0.42-3.04 .82 1.30 0.41-4.09 .66
Sex, ref male
Female 1.42 0.64-3.17 .39 1.22 0.81-2.93 .66 0.79 0.39-1.59 .51 0.44 0.19-0.99 .05
Marital status, ref married/cohabiting
Single, divorced, widowed,
or separated
1.64 0.78-3.47 .19 1.34 0.60-2.97 .47 1.34 0.77-2.35 .30 1.14 0.60-2.17 .68
Education, ref school level
Further education 0.81 0.37-1.75 .58 0.77 0.34-1.71 .52 0.82 0.44-1.52 .52 0.83 0.40-1.69 .60
University/poly 0.29 0.07-1.28 .10 0.27 0.06-1.26 .10 0.89 0.38-2.07 .78 0.54 0.21-1.42 .21
Tumor site, ref oral cavity
Oropharynx 0.48 0.20-1.16 .10 0.24 0.07-0.83 .02 0.85 0.45-1.61 .62 1.16 0.46-2.93 .76
Larynx 0.72 0.30-1.72 .46 0.57 0.18-1.82 .34 0.24 0.11-0.56 .001 0.15 0.05-0.48 .001
TNM classification, ref early
Advanced 0.97 0.47-2.00 .94 0.91 0.31-261 .85 0.65 0.37-1.14 .14 0.47 0.20-1.09 .08
Comorbidity, ref none or mild
Moderate or severe 1.91 0.85-4.28 .12 1.98 0.82-4.76 .13 2.84 1.44-5.60 .003 3.12 1.39-7.01 .006
Treatment received, ref surgery only
Surgery1 adjunct 0.70 0.22-2.20 .54 1.17 0.33-4.21 .81 0.50 0.22-1.13 .10 0.60 0.22-1.65 .32
Combined chemoradiotherapy 1.21 0.48-3.05 .68 3.14 0.74-13.3 .12 0.72 0.35-1.46 .35 0.96 0.29-3.17 .95
Radiotherapy only 0.77 0.26-2.29 .64 1.23 0.32-4.71 .76 0.50 0.22-1.13 .10 1.18 0.37-3.80 .78
BL alcohol consumption,
ref “healthy”
Unhealthy 0.85 0.41-1.76 .67 0.86 0.39-1.88 .70 1.11 0.61-2.03 .73 0.90 0.45-1.81 .77
Abbreviations: BL, baseline; CI, confidence interval; OR, odds ratio; ref, reference.
aMutually adjusted for all exposures and confounders .
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the recommended weekly maximum units of alcohol and
21% were current smokers at diagnosis. Twelve months after
diagnosis, 60% of people who smoked and 31% of people
who consumed alcohol above the recommended weekly limit
at baseline had made positive changes to these behaviors.
However, these changes were not 1-way or static over the
first year after diagnosis. We found that being male, having a
laryngeal tumor, and being a former or current smoker were
associated with high alcohol consumption at 12 months.
Continuing to smoke at 12 months was associated with being
male, having an oral cavity or oropharyngeal tumor, and hav-
ing more severe comorbidities at diagnosis.
The proportion of current smokers at diagnosis who had
quit smoking at 12 months in our study (60%) is comparable
to a similar population of people with head and neck cancer
(58%),18 and higher than in people with other smoking-
related cancers (46%).34 The reduction in the prevalence of
high alcohol consumption in our study (54% to 41%) was
less than the reduction in prevalence of “problem drinking”
(25% to 11%) reported by Duffy et al.18 Although, our reduc-
tion in “harmful” alcohol consumption (17% to 8%) was
more comparable, suggesting the threshold for “harmful”
consumption in our study may be a more appropriate proxy
measure of problem drinking.
The changes in behavior we observed in our study were
not stable over the first 12 months after diagnosis. The
reduced prevalence of high alcohol consumption from 54%
at diagnosis to 41% at 12 months overlooks a larger reduc-
tion at 4 months (54% to 35%); it also hides the fact that a
large proportion (31%) of high consumers at 12 months had
increased their alcohol consumption from 4 months. In com-
parison, smoking prevalence in this cohort reduced between
diagnosis and 4 months and this reduction was maintained at
12 months. Most nonsmokers and former smokers at diagno-
sis remained nonsmokers but a high proportion of smokers at
12 months (44%) had previously quit smoking either before
diagnosis or by 4 months postdiagnosis.
We considered a range of potential factors that might be
associated with smoking or alcohol consumption. Few were
associated with smoking at 12 months. The reduction in
odds of smoking at 12 months among smokers at diagnosis
with laryngeal cancer compared to oral cavity cancer is in
agreement with previous studies.32,35 People who attribute
the cause of their head and neck cancer to their own past
behavior are more likely to stop smoking,36 and smoking is
most strongly associated with developing laryngeal cancer
compared with other head and neck cancers.37 Furthermore,
the etiology of head and neck cancer may be changing to
include other causal factors, in particular, the emergence of
human papillomavirus as a likely cause of oropharyngeal
cancer.38 As a result, people with laryngeal cancers com-
pared with other head and neck cancers may receive clearer
messages about the potential role of smoking in their
diagnosis, leading to a reduction in smoking prevalence in
this group.
In our study, people with more severe comorbidities had
increased odds of resumption or of continued smoking at 4
months, and continued smoking at 12 months. This contrasts
with previous studies covering a wider range of cancer diag-
noses.39,40 We adjusted for severity of comorbidity by using
the Adult Comorbidity Evaluation-27, whereas other studies
have adjusted for numbers of comorbidities, which may
explain our contrasting results.
The absence of associations in our study between treat-
ment and smoking at 12 months contrasts with previous stud-
ies. Functional difficulties after surgery25 or the complexity
and/or longevity of treatment32 were suggested as explana-
tions for lower odds of continued smoking in people receiv-
ing surgery with or without adjunct therapy compared to
radiotherapy only. Our findings with respect to treatment,
therefore, warrant further exploration. Similar to previous
studies, treatment was not associated with alcohol consump-
tion at 12 months.18,23 We found strong associations between
treatment and alcohol consumption at 4 months, with
reduced odds of high consumption in people receiving chem-
otherapy, radiotherapy, or combined therapy rather than sur-
gery alone, irrespective of consumption at diagnosis. This
may reflect the continued impact of chemotherapies and
radiotherapies on swallowing, taste, or appetite at 4 months,
whereas, people who had surgery may have been several
weeks into their postoperative recovery period. The absence
of associations between treatment and alcohol consumption
at 12 months suggests that side effects of chemotherapies
and radiotherapies have a transient rather than sustained
impact on alcohol consumption.
In our study, the relatively high proportion of people
who stopped smoking or reduced their alcohol consumption
by 4 months compared with between 4 and 12 months sug-
gests that positive behavior change in this population is most
likely in the early months immediately after diagnosis. This
compares favorably with the optimal time frame for a smok-
ing cessation intervention in people newly diagnosed with
head and cancer.25 It is also a similar time frame in which
treatment side effects might be affecting smoking behavior,
however, the absence of associations between treatment and
change in smoking at 4 months in our study does not support
this being an important factor. For some people in our study,
health behaviors that worsened or improvements were not
sustained over the 12 months. Interventions may, therefore,
be more successful if they also support the maintenance of
behavior change in the 12 months after diagnosis.
We found strong associations between being men and
high alcohol consumption, which persisted when using previ-
ous sex-specific thresholds for alcohol consumption. This
contrasts with previous studies, which found no association
of sex with continuing to consume any alcohol23 or with
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problem drinking behavior.18 The authors included alcohol
abuse status in their analysis, which has separately been
found to be more prevalent in men at the time of diagnosis
of head and neck cancer.18 It may, therefore, be that the sex
association we found is partially or fully explained by a
higher prevalence of problem drinking behavior in men in
our cohort.
People who continue to smoke and/or consume higher
amounts of alcohol after diagnosis have a worse progno-
sis.9,10,41 We found an association between being a current
or former smoker at diagnosis and high alcohol consumption
at 12 months, in agreement with a previous study.18 This
group of people who both drink and smoke are less likely to
change these behaviors but may be likely to benefit the most
from effective interventions that target both behaviors
because they have a multiplicative effect compared with tar-
geting each behavior individually.42
Compared with previous studies in this area, our study
has 2 important strengths. We used data from a large pro-
spective clinical cohort with measures of smoking and alco-
hol consumption at 3 time points during the first 12 months
after diagnosis. The size of our cohort allowed us to stratify
our regression models by health behaviors at diagnosis,
because reducing unhealthy behaviors is a different outcome
from maintaining healthy behaviors. There are several weak-
nesses to our study. We relied on self-reported measures for
our demographic and health behavior measures. Our meas-
ures of smoking and alcohol behavior in particular may be
affected by recall and self-reported biases. For smoking, this
may have led to an underestimate of the prevalence of smok-
ing,43 whereas these biases seem to be less of a concern for
alcohol consumption.44 Because we did not study change in
the volume of alcohol consumed directly but change in cate-
gorized consumption, our analyses should be less sensitive to
minor differences due to recall bias. These biases could be
further reduced by using objective biomarkers rather than
self-reported measures. Cotinine levels are an accepted indi-
cator of smoking status43 but currently there is not a suitable
biomarker of alcohol consumption except for acute consump-
tion. Furthermore, we were only able to focus on consump-
tion rather than measures of lifetime exposure to alcohol or
tobacco smoke, which was either not collected (alcohol) or
had a large proportion of missing data (smoking). The behav-
ior data collected at 4 months are likely to be from a mixture
of people who have completed their treatment alongside
those still in active treatment, which may mask behavior
change and make it harder to interpret because people are at
different stages of their treatment. We also had a high pro-
portion of missing data, which may have introduced bias but
we did explore the potential impact of this through sensitivity
analyses.
Further studies in this population should evaluate
whether these short-term changes in smoking and alcohol
consumption persist beyond 1 year and the prognostic impli-
cations of these changes. Given the emergence of human
papillomavirus as a significant prognostic marker, it might
also be of interest to explore whether the benefits of health
behavior changes persist within human papillomavirus-
positive head and neck cancers.
5 | CONCLUSIONS
The 12-month period immediately after a cancer diagnosis is
characterized by important reductions in alcohol consump-
tion and smoking prevalence. However, the majority of high
alcohol consumers at diagnosis do not reduce their consump-
tion, and may benefit from assistance both to reduce their
consumption and maintain this reduction. Most current
smokers at diagnosis stop smoking by 12 months, but former
smokers are also at risk of restarting. Furthermore, people
who continue smoking 4 months after diagnosis are likely to
continue up to 12 months.
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